Distinguishing Characteristics between Pandemic 2009–2010 Influenza A (H1N1) and Other Viruses in Patients Hospitalized with Respiratory Illness by Chan, Philip A. et al.
Distinguishing Characteristics between Pandemic 2009–
2010 Influenza A (H1N1) and Other Viruses in Patients
Hospitalized with Respiratory Illness
Philip A. Chan
1,2, Leonard A. Mermel
1,2, Sarah B. Andrea
3, Russell McCulloh
4,5, John P. Mills
2, Ignacio
Echenique
2, Emily Leveen
2, Natasha Rybak
2, Cheston Cunha
2, Jason T. Machan
6, Terrance T. Healey
7,
Kimberle C. Chapin
2,3*
1Division of Infectious Diseases, Rhode Island Hospital, Providence, Rhode Island, United States of America, 2Department of Medicine, Alpert Medical School of Brown
University, Providence, Rhode Island, United States of America, 3Department of Pathology, Rhode Island Hospital, Providence, Rhode Island, United States of America,
4Division of Pediatric Infectious Diseases, Rhode Island Hospital, Providence, Rhode Island, United States of America, 5Department of Pediatrics, Alpert Medical School of
Brown University, Providence, Rhode Island, United States of America, 6Department of Orthopedics and Surgery, Rhode Island Hospital, Providence, Rhode Island, United
States of America, 7Department of Radiology, Rhode Island Hospital, Providence, Rhode Island, United States of America
Abstract
Background: Differences in clinical presentation and outcomes among patients infected with pandemic 2009 influenza A
H1N1 (pH1N1) compared to other respiratory viruses have not been fully elucidated.
Methodology/Principal Findings: A retrospective study was performed of all hospitalized patients at the peak of the pH1N1
season in whom a single respiratory virus was detected by a molecular assay targeting 18 viruses/subtypes (RVP, Luminex
xTAG). Fifty-two percent (615/1192) of patients from October, 2009 to December, 2009 had a single respiratory virus (291
pH1N1; 207 rhinovirus; 45 RSV A/B; 37 parainfluenza; 27 adenovirus; 6 coronavirus; and 2 metapneumovirus). No seasonal
influenza A or B was detected. Individuals with pH1N1, compared to other viruses, were more likely to present with fever
(92% & 70%), cough (92% & 86%), sore throat (32% & 16%), nausea (31% & 8%), vomiting (39% & 30%), abdominal pain (14%
& 7%), and a lower white blood count (8,500/L & 13,600/L, all p-values,0.05). In patients with cough and gastrointestinal
complaints, the presence of subjective fever/chills independently raised the likelihood of pH1N1 (OR 10). Fifty-five percent
(336/615) of our cohort received antibacterial agents, 63% (385/615) received oseltamivir, and 41% (252/615) received
steroids. The mortality rate of our cohort was 1% (7/615) and was higher in individuals with pH1N1 compared to other
viruses (2.1% & 0.3%, respectively; p=0.04).
Conclusions/Significance: During the peak pandemic 2009–2010 influenza season in Rhode Island, nearly half of patients
admitted with influenza-like symptoms had respiratory viruses other than influenza A. A high proportion of patients were
treated with antibiotics and pH1N1 infection had higher mortality compared to other respiratory viruses.
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Introduction
Viral respiratory illnesses are responsible for large numbers of
hospital admissions each year leading to substantial morbidity and
mortality [1]. The etiologic agents include a diverse group of
viruses, such as influenza A which is responsible for intermittent
pandemics [2]. Reassortment of swine-origin and human strains
led to circulating pH1N1 [3,4] and a significant increase in
hospital admissions during the 2009–2010 influenza season.
Timely identification of influenza is important as the adminis-
tration of neuraminidase inhibitors may limit duration and severity
of illness if given early [5]. Rapid tests were found to be insensitive
in the diagnosis of pH1N1 [6] and unable to subtype the influenza
virus. Molecular techniques replaced some of these tests, but the
availability, expense and technical training limited widespread use
of this technology [7]. Therefore, many clinicians relied on clinical
symptoms to diagnose influenza during the pandemic [8].
The classic influenza-like illness (ILI), defined as fever and
cough and/or sore throat, is often used to distinguish influenza
from other respiratory viruses. However, other viruses such as
respiratory syncytial virus (RSV A/B), rhinovirus, parainfluenza,
adenovirus, metapneumovirus, and coronavirus, can cause a
similar illness and circulate at the same time as influenza [1,9].
Using ILI symptoms to diagnose influenza is neither sensitive nor
specific [10,11]. Other symptoms reported during the pandemic
included gastrointestinal complaints [12–19], leukopenia
[14,20,21], elevated aminotransferase levels [14], thrombocytope-
nia and other laboratory abnormalities [14,20–24]. Although the
PLoS ONE | www.plosone.org 1 September 2011 | Volume 6 | Issue 9 | e24734clinical characteristics of pH1N1 infection may be similar to
seasonal influenza [25,26], there is scant data in the literature
comparing pH1N1 with other respiratory viruses.
The inability to reliably diagnose a viral respiratory infection
such as influenza A, often leads to coverage of possible bacterial
etiologies [27]. Overuse of antibiotics is not without consequence
and can lead to complications including Clostridium difficile infection
and high rates of resistance [28]. Thus, an accurate diagnosis of
influenza and other respiratory viral infections is important to
avoid overuse of antibacterial agents and direct appropriate
antiviral therapy.
In response to the diagnostic challenges presented by influenza
infection, our hospital system instituted a polymerase chain
reaction (PCR)-based molecular panel that was able to identify
18 different respiratory viruses. The aim of this study was to
examine differences in clinical, laboratory and radiographic
findings between pH1N1 and other respiratory viruses with the
goal to assist clinicians in more effectively diagnosing and treating
pH1N1. To our knowledge, this is the first study to directly
compare clinical parameters of pH1N1 to other respiratory viruses
using a sensitive molecular diagnostic methodology in a large
cohort.
Results
During our peak pH1N1 season, 1,438 RVP samples were
collected. Of these, 1192 were from inpatients (340 samples in
patients ,5 years, 240 samples 5–18 years, and 612 samples .19
years). Six-hundred and fifteen patients with positive results were
included in the final analysis (Figure 1) with a mean age of 20 years
(range: 0–97 years). Forty-seven percent of patients had pH1N1
and 53% had another respiratory virus with rhinovirus being the
second most prevalent in the population analyzed (34%, Table 1).
Fewer patients with pH1N1 were under the age of five years
compared to those with other viruses and individuals with pH1N1
were less likely to have cardiac co-morbidities, malignancy, or be
admitted from a nursing home. Individuals with pH1N1 were
more likely to report a sick contact or to use tobacco.
Individuals with pH1N1 were more likely to present with the
following symptoms when compared to those with other
respiratory viruses: subjective fever or chills, sore throat, nausea,
vomiting, abdominal pain, weakness, fatigue, headache, myalgias,
and chest pain. Patients with other respiratory viruses were more
likely to present with changes in mental status including dizziness
or lethargy (Table 2).
On presentation to the emergency room, patients with pH1N1
exhibited a higher maximum temperature, lower maximum heart
rate, respiratory rate, systolic blood pressure, and oxygen
saturation (Table 3). Patients with pH1N1 were more likely to
have lower white blood counts, platelet counts, and potassium
levels. Alternatively, patients with pH1N1 were more likely to have
higher hemoglobin/hematocrit and albumin levels.
Of the 529 patients who received a chest radiograph, a greater
number of patients with pH1N1 had no acute findings compared
to other respiratory viruses (Table 4). Other respiratory viruses
were more likely to have an interstitial opacity consistent with viral
infection on chest radiograph. Thirty percent (161/529) of patients
with a chest radiograph had focal or multi-focal airspace findings.
Most patients with pH1N1 (79.0%) received oseltamivir. More
than half received antibacterial agents, and one-third received
steroids (Table 5). Of the total cohort, only 9.6% had a sputum
sample of which 27% were positive for a potential pathogenic
Figure 1. Study inclusion algorithm.
doi:10.1371/journal.pone.0024734.g001
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evidence of acute disease or interstitial opacities indicative of viral
infection on chest radiograph received antibacterial agents. Forty-
six percent of the total cohort had blood sentfor culture during their
hospitalization, of which 2.5% grew a potential pathogenic microbe
(i.e., coagulase-negative staphylococci and other potential skin
contaminants were excluded). Twelve percent of the total cohort
had a Legionella urine antigen test performed and all were negative.
There was no difference between patients infected with pH1N1 or
another respiratory viruses regarding admission to an intensive care
unit, use of pressors or requirement for intubation (Table 5).
However,individualswith pH1N1weremorelikelytorequire bilevel
positive airway pressure ventilation. Individuals with other respira-
tory viruses were more likely to receive inhaled bronchodilators or
nebulizer therapy in the emergency department. Seven patients
(1.1%)inthecohortdied andtheseindividualswere morelikelyto be
infected with pH1N1 (2.1% vs. 0.3%, p,0.05).
In patients with cough, the presence of subjective fever/chills
independently increased the likelihood of pH1N1 infection
(Table 6). In patients with cough and gastrointestinal complaints,
subjective fever/chills independently increased the likelihood of
having pH1N1. Using fever alone did not raise the likelihood of
having influenza infection versus another respiratory virus. Using
age as a covariate, patients 19 to 59 years of age had the highest
likelihood of presenting with pH1N1 compared to other age
groups.
An age-adjusted analysis was performed to assess if any factors
were found that significantly impacted the likelihood of patients
Table 3. Clinical characteristics of patients with pandemic influenza A (pH1N1) compared to other respiratory viruses.
Pandemic Influenza A (H1N1) Other Respiratory Viruses
Mean [95% CI] Min Max Mean [95% CI] Min Max p-value
Duration of Symptoms (days) 3.3 [2.8–3.9] 1.0 60.0 4.0 [3.4–4.5] 1.0 56.0 0.10
Max Temperature (
oF) 100.9 [100.7–101.1] 96.0 106.5 100.2 [99.9–100.4] 92.4 110.3 ,0.01
Max Heart Rate (/min) 128.6 [125.1–132.0] 65.0 220.0 140.8 [136.8–144.7] 19.0 226 ,0.01
Max Respiratory Rate (/min) 31.5 [29.9–33.1] 2.0 80.0 39.0 [37.0–41.1] 14.0 168.0 ,0.01
Lowest SBP
a (mmHG) 105.7 [103.5–108.0] 43.0 176.0 111.1 [108.5–113.6] 11.0 202.0 ,0.01
Corresponding DBP
b (mmHG) 60.1 [58.6–61.7] 12.0 98.0 64.9 [63.1–66.6] 0.0 133.0 ,0.01
Lowest Oxygen Saturation (%) 93.9 [93.2–94.7] 30.0 100.0 95.2 [94.8–95.6] 73.0 100.0 ,0.01
Sodium (meq/L) 136.8 [136.4–137.2] 127.0 146.0 136.7 [136.1–137.4] 114.0 144.0 0.92
Potassium (meq/L) 3.9 [3.8–4.0] 2.6 6.1 4.1 [4.0–4.1] 2.5 6.0 ,0.01
Bicarbonate (meq/L) 24.3 [23.9–24.8] 13.0 36.0 25.6 [24.0–27.2] 12.0 107.0 0.13
Chloride (meq/L) 102.6 [102.0–103.1] 89.0 114.0 101.8 [100.2–103.4] 21.0 116.0 0.36
Creatinine (mg/dl) 0.94 [0.77–1.11] 0.13 10.25 0.95 [0.58–1.32] 0.09 28.0 0.95
Blood urea nitrogen (mg/dl) 13.2 [11.4–14.9] 2.0 118.0 12.6 [11.3–13.8] 0.53 60.0 0.59
Glucose (mg/dl) 135.6 [126.9–144.4] 51.0 575.0 131.0 [123.1–138.9] 0.66 377.0 0.44
White blood count (610
3/ml) 8.5 [8.1–9.0] 0.7 21.5 13.6 [12.3–14.9] 0.20 86.5 ,0.01
Bands (%) 2.8 [2.0–3.6] 0.0 45.0 2.5 [1.8–3.2] 0.0 36.0 0.61
Hemoglobin (g/dl) 13.0 [12.8–13.3] 7.2 18.3 12.2 [11.9–12.5] 6.3 17.8 ,0.01
Hematocrit (%) 38.0 [37.3–38.7] 21.8 52.1 35.9 [35.1–36.8] 19.1 51.7 ,0.01
Platelets (610
3/ml) 229.7 [218.6–240.8] 13.0 539.0 288.7 [271.2–306.2] 16.0 700.0 ,0.01
Lactate (meq/L) 2.4 [1.3–3.5] 0.4 23.6 2.0 [1.5–2.4] 0.6 7.4 0.44
AST (IU/L) 52.0 [39.5–64.4] 14.0 332.0 133.3 [20.12–266.8] 11.0 3273.0 0.23
ALT (IU/L) 36.6 [29.3–44.0] 9.0 148.0 122.2 [10.7–233.7] 8.0 2560.0 0.13
Total Bilirubin (mg/dl) 0.8 [0.7–0.9] 0.2 2.0 1.2 [0.7–1.6] 0.2 11.2 0.08
Direct Bilirubin (mg/dl) 0.2 [0.1–0.2] 0.1 0.8 0.2 [0.1–0.3] 0.1 1.4 0.21
Alkaline Phosphate (IU/L) 95.2 [79.1–111.2] 31.0 277.0 114.2 [91.0–137.4] 48.0 477.0 0.18
Protein (g/dl) 6.7 [6.5–6.9] 5.0 9.0 6.5 [6.2–6.7] 4.1 8.8 0.13
Albumin (g/dl) 3.5 [3.3–3.6] 2.2 4.9 3.2 [2.9–3.4] 1.5 4.3 0.02
PTT (sec) 32.9 [27.4–38.5] 22.3 75.5 29.0 [23.5–34.4] 11.8 41.9 0.31
PT (sec) 15.8 [13.2–18.4] 11.5 34.9 18.8 [13.3–24.3] 11.5 49.6 0.31
INR 1.4 [1.1–1.7] 0.9 3.6 1.5 [1.1–1.8] 0.9 3.1 0.80
Creatine Kinase (IU//L) 304.3 [166.4–442.1] 15.0 2548.0 304.6 [37.9–571.2] 14.0 2368.0 1.00
MB Fraction (%) 1.7 [0.5–2.9] 0.0 15.2 3.6 [20.04–7.2] 0.0 18.7 0.30
Troponin I (ng/ml) 0.24 [0.10–0.37] 0.08 2.8 0.82 [20.15–1.78] 0.03 9.0 0.23
aSystolic blood pressure;
bDiastolic blood pressure; CI=confidence intervals; PT=prothrombin time; PTT=partial thromboplastin time; INR=international normalized ratio; AST=aspartate
aminotransferase; ALT=alanine aminotransferase.
doi:10.1371/journal.pone.0024734.t003
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PLoS ONE | www.plosone.org 6 September 2011 | Volume 6 | Issue 9 | e24734presenting with pH1N1. Age was a significant variable for those
patients who had cancer (,5 years OR 5.7, 95% CI 0.51–63.6; 5–
18 years OR 0.26, 95% CI 0.023–3.0; 19 and older OR 0.11, 95%
CI 0.041–0.31), neurological symptoms (,5 years OR 2.67, 95%
CI 0.98–7.3; 5–18 years OR 1.27, 95% CI 0.51–3.17; 19 and
older OR 0.52 95% CI 0.23–1.17), or dyspnea (,5 years OR
0.33, 95% CI 0.18–0.61; 5–18 years OR 0.26, 95% CI 0.29–1.21;
19 and older OR 0.95, 95% CI 0.56–1.60). Age was also found to
have a significant affect on sodium, creatinine, hematocrit, heart
rate, diastolic blood pressure, the use of nebulizers, and the
administration of antibiotics across different age groups (,5 years,
5–18 years, and 19 years and older). Patients with pH1N1 who
were younger tended to be given more antibiotics (,5 years OR
1.30, 95% CI 0.73–2.33; 5–18 years OR 1.63, 95% CI 0.82–3.2;
19 and older OR 0.42, 95% CI 0.24–0.74). Age did not have a
significant impact on any other variables.
Discussion
In patients with viral respiratory infections, diagnosis of
influenza is important to provide timely and efficient treatment
with neuraminidase inhibitors. Rapid antigen tests were insensitive
in the diagnosis of influenza during the 2009–2010 pandemic
season [29,6,30]. Furthermore, these tests could not distinguish
between different influenza A subtypes [31]. Seasonal influenza A
(H1N1) was resistant to oseltamivir, whereas pH1N1 was not,
making this a critical distinction [32]. While state public health
labs had a CDC-based PCR assay for distinguishing influenza
subtypes, an FDA-cleared product for clinical laboratories was
delayed [33]. Therefore, many institutions, including our own,
implemented a molecular-based test to diagnose influenza A [34].
The Luminex xTAG RVP was highly sensitive and able to
distinguish 18 viruses causing respiratory infections, including
different influenza subtypes.
With the introduction and effectiveness of molecular testing, one
goal is more efficient use of antimicrobials and the reduction of
unnecessary antibiotic use. Despite the relatively rapid turnaround
time of the PCR-based tests, greater than half of the patients in our
cohort with documented viral infections received antibacterial
agents, presumably for empiric coverage of bacterial pneumonia.
Furthermore, almost half of patients without influenza received
oseltamivir. As such, implementation of rapid diagnostic testing for
respiratory pathogens alone may not limit antibiotic use without
other interventions. These data suggest overuse of antibacterial
and antiviral agents and an opportunity for a robust antimicrobial
stewardship program.
Clinical characteristics of hospitalized patients with pH1N1
were variable. Fever and cough, two criteria for ILI, often occur in
influenza A patients [3,14,12,15–18,20,21,24]. Although more
patients with pH1N1 presented with fever and sore throat
compared to those with other viruses in our population, the
difference was not enough to make a firm clinical diagnosis of
influenza. Furthermore, there was no significant difference in
cough alone between patients infected with pH1N1 and other
respiratory viruses. However, fever, cough, and gastrointestinal
symptoms increased the likelihood of pH1N1 almost 10-fold in the
pediatric population and may be useful as a preliminary guide to
prompt clinicians to treat influenza infection. Chest radiographs
may be useful in diagnosing superimposed bacterial infection.
While airspace disease was observed more often in patients with
non-influenza viruses, there were no chest radiographic findings
that distinguish influenza infection. Over half of patients with
pH1N1 had non-specific findings on chest radiograph as
previously reported [24].
Our study supports previous findings that pH1N1 tends to
infect younger adults, sparing the elderly and young children
[3,14,15,17,19,18,20,21]. We found lower rates of influenza from
nursing home patients reflecting this age distribution. Of those
that died or were hospitalized, many had co-morbidities as previ-
ously reported [15,17,19,21,35,36]. In contrast to other studies
[15,37,38,21,19], we did not find a high infection or mortality rate
during pregnancy but our study was underpowered due to the low
number of pregnant women in our cohort.
The mortality rate of 2.1% for hospitalized patients with
pH1N1 infection in our cohort was lower than other reports
[14,15]. Despite this, it was significantly higher than the mortality
associated with other respiratory viral infections and highlights the
importance of accurate diagnosis and early treatment of influenza
infection.
Table 6. Likelihood of patients with clinical characteristics having pandemic 2009 influenza A (pH1N1) using multiple logistic
regressions.
Likelihood of having pandemic 2009 influenza A (H1N1) OR [95% CI]
Subjective fever/chills in patients with cough and gastrointestinal complaints 9.96 [4.04–24.59]
Subjective fever/chills in patients with cough and no gastrointestinal complaints 4.02 [2.03–7.99]
Subjective fever/chills in patients without cough or gastrointestinal complaints 0.70 [0.20–2.47]
Cough in patients with subjective fevers/chills 1.79 [0.97–3.31]
Cough in patients without subjective fevers/chills 0.31 [0.09–1.01]
Gastrointestinal complaints in patients with subjective fevers/chills 2.29 [1.57–3.34]
Gastrointestinal complaints in patients without subjective fevers/chills 0.92 [0.34–2.54]
$60 years-old versus 19–59 years-old 0.22 [0.11–0.44]
$60 years-old versus 5–18 years-old 0.27 [0.13–0.56]
$60 years-old versus ,5 years-old 1.30 [0.65–2.58]
19–59 years-old versus 5–18 years-old 1.26 [0.78–2.04]
19–59 years-old versus ,5 years-old 5.98 [3.86–9.24]
5–18 years-old versus ,5 years-old 4.75 [3.02–7.47]
OR=odds ratio; CI=confidence intervals.
doi:10.1371/journal.pone.0024734.t006
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PLoS ONE | www.plosone.org 7 September 2011 | Volume 6 | Issue 9 | e24734Aside from the retrospective nature of our study, a potential
limitation was the small number of pregnant women likely due to
the presence of a neighboring obstetrics and gynecologic hospital. A
second limitation was the time period for which patients presenting
with ILI were evaluated (6 weeks at the peak of the pandemic)
whereas a typical respiratory season would be for several months
and include a greater variety of viruses, especially in the pediatric
population. In fact, our data (not shown) does indicate that after the
pandemic wave at our institution, a typical peak for RSV,
metapneumovirus and parainfluenza viruses followed the presence
of pH1N1, much like the rest of the country. A third limitation was
that pH1N1 confirmatory testing was not performed for all non-
subtypeable influenza A viruses. However, recent literature suggests
that 100% of non-subtypeable influenza A H1 identified by the
xTAG RVP was pH1N1 [39] and that misinterpretation is
uncommon [40]. In addition, our initial investigation of a large
number of strains early in the pandemic with the CDC PCR assay
confirmed these findings. Many prior studies only assessed the
clinical characteristics of patients with influenza or compared to
individuals who’s respiratory tests were negative for influenza, but
they did not further delineate those without influenza or positive for
another virus [14,16,18,20,21,25,26]. We set out to compare
pandemic 2009 influenza A (H1N1) to other respiratory viruses in
patients with ILI. To our knowledge, these results provide the first
comparison of clinical characteristics between pH1N1 and other
common respiratory viruses.
While a specific clinical presentation could not confirm pH1N1
in patients with cough and gastrointestinal complaints, the
presence of subjective fever and/or chills increased the likelihood
of pH1N1 infection versus another virus. Respiratory infection
with pH1N1 infection more often resulted in death compared to
other respiratory viruses and should be treated aggressively with
supportive measures and antiviral medications. Despite the use of
RVP testing, many influenza-infected patients received antibacte-
rial agents and many patients without influenza received antivirals.
Use of a highly accurate RVP in conjunction with a robust
antimicrobial stewardship program will be necessary to assure
prudent antibacterial and antiviral agent use in the future.
Materials and Methods
Ethics
The study was approved by the Rhode Island Hospital
institutional review board. A waiver of informed consent was
obtained before onset of the study.
Study Design
A retrospective review was performed of all individuals
presenting to our hospital system between October 16, 2009 and
December 1, 2009 who had a positive respiratory viral panel
(RVP, Luminex xTAGH; Luminex Corporation, Austin, TX)
result from a nasopharyngeal swab specimen and who were
subsequently hospitalized. Our hospital system consists of Rhode
Island Hospital, a tertiary care center licensed for 719 beds,
including Hasbro Children’s Hospital, as well as The Miriam,
Newport and Bradley Hospitals licensed for 247, 129 and 60 beds,
respectively. All respiratory specimens were processed in the
microbiology facility at Rhode Island Hospital. Our 18-virus panel
detected influenza A/B (H1, H3, and non-subtypeable A
consistent with pH1N1), respiratory syncytial virus A and B,
adenovirus, metapneumovirus, rhinovirus/enterovirus, parainflu-
enza 1,2,3,4 and coronaviruses (NL63, OC43, HKU1, and 229E).
The panel determined influenza A as seasonal human influenza A
(H1N1), seasonal human influenza A (H3N2) or a non-subtypeable
influenza A virus consistent with pH1N1. The Rhode Island
Department of Health (DOH) confirmed the initial 30 specimens
detected by the xTAG RVP as non-subtypeable influenza A H1 as
pH1N1, utilizing primers and probes distributed by the Center for
Disease Control and Prevention (CDC). Thus, subsequent non-
subtypeable influenza A H1 detected by the RVP were reported as
pH1N1.
Statistical Analysis
Medical records of all cases were reviewed. Initial chest
radiographs and subsequent chest CTs were reviewed and
interpreted independently by three board-certified radiologists.
Consensuses on all findings were reached. Logistic regressions
were used to examine the relationships between variables and
patients testing positive for pH1N1 compared with patients testing
positive for a different respiratory virus. Subsequently, a series of
multiple logistic regressions were constructed based on integrating
the results from previous literature and our logistic regression
results. Individual interactions between variables were checked
and those with p.0.15 were retained, arriving at a final model.
Special effort was placed on using symptoms and other clinical
information. Co-linearity between predictors was minimized by
forming theoretically and clinically guided composites as needed.
All predictors were tested for an interaction with different age
categories (,5 years, 5–18 years, 19 years and older) with regards
to predicting pH1N1 in logistic regressions. Models included main
effects for the predictor, age, and the interaction of the two. When
a statistically significant interaction was detected, the simple effects
of the predictors were described in terms of their effects within age
categories. Those which did not significantly interact with age
were described in terms of their main effect.
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